104 related articles for article (PubMed ID: 22043042)
21. Novel therapeutic approaches to the treatment of metastatic breast cancer.
Fernández Y; Cueva J; Palomo AG; Ramos M; de Juan A; Calvo L; García-Mata J; García-Teijido P; Peláez I; García-Estévez L
Cancer Treat Rev; 2010 Feb; 36(1):33-42. PubMed ID: 19883980
[TBL] [Abstract][Full Text] [Related]
22. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
23. Genetic risk of breast cancer.
Nasir A; Shackelford RE; Anwar F; Yeatman TJ
Minerva Endocrinol; 2009 Dec; 34(4):295-309. PubMed ID: 20046159
[TBL] [Abstract][Full Text] [Related]
24. New agents in development for breast cancer.
Gao XP; Liu F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):68-74. PubMed ID: 17218855
[TBL] [Abstract][Full Text] [Related]
25. Strategies to translate preclinical information to breast cancer patient benefit.
Daidone MG; Zaffaroni N; Cappelletti V
J Natl Cancer Inst Monogr; 2011; 2011(43):55-9. PubMed ID: 22043041
[TBL] [Abstract][Full Text] [Related]
26. Genomic strategies for personalized cancer therapy.
Garman KS; Nevins JR; Potti A
Hum Mol Genet; 2007 Oct; 16 Spec No. 2():R226-32. PubMed ID: 17911165
[TBL] [Abstract][Full Text] [Related]
27. Test may help predict chemotherapy response and survival in breast cancer.
Printz C
Cancer; 2011 Oct; 117(19):4339. PubMed ID: 21928334
[No Abstract] [Full Text] [Related]
28. Is multidrug resistance relevant in breast cancer?
Wishart GC; Kaye SB
Eur J Surg Oncol; 1991 Oct; 17(5):485-8. PubMed ID: 1682166
[TBL] [Abstract][Full Text] [Related]
29. [Individualized treatment of breast cancer].
Eucker J; Possinger K
Dtsch Med Wochenschr; 2011 Mar; 136(10):486-91. PubMed ID: 21365526
[TBL] [Abstract][Full Text] [Related]
30. Truncated HER2: implications for HER2-targeted therapeutics.
Zagozdzon R; Gallagher WM; Crown J
Drug Discov Today; 2011 Sep; 16(17-18):810-6. PubMed ID: 21704182
[TBL] [Abstract][Full Text] [Related]
31. How next-generation sequencing could change cancer care.
O'Hanlon LH
J Natl Cancer Inst; 2013 Jun; 105(12):836-8. PubMed ID: 23733908
[No Abstract] [Full Text] [Related]
32. Personalized systemic treatment for breast cancer patients: is it a reality?
Shimizu C; Fujiwara Y
Breast Cancer; 2008; 15(2):141-4. PubMed ID: 18274835
[TBL] [Abstract][Full Text] [Related]
33. Knowledge of genomic testing among early-stage breast cancer patients.
Richman AR; Tzeng JP; Carey LA; Retèl VP; Brewer NT
Psychooncology; 2011 Jan; 20(1):28-35. PubMed ID: 20200857
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer management: opportunities and barriers to an individualized approach.
Perez EA
Oncologist; 2011; 16 Suppl 1():20-2. PubMed ID: 21278437
[TBL] [Abstract][Full Text] [Related]
35. Drug discovery for breast cancer and co-instantaneous cardiovascular disease: what is the future?
Yin L; Hu Q
Future Med Chem; 2013 Mar; 5(4):359-62. PubMed ID: 23495679
[No Abstract] [Full Text] [Related]
36. Mutation matters in precision medicine: A future to believe in.
Dey N; Williams C; Leyland-Jones B; De P
Cancer Treat Rev; 2017 Apr; 55():136-149. PubMed ID: 28371665
[TBL] [Abstract][Full Text] [Related]
37. Patient-derived tumour xenografts as models for breast cancer drug development.
Marangoni E; Poupon MF
Curr Opin Oncol; 2014 Nov; 26(6):556-61. PubMed ID: 25188472
[TBL] [Abstract][Full Text] [Related]
38. New concepts in breast cancer genomics and genetics.
Goncalves R; Warner WA; Luo J; Ellis MJ
Breast Cancer Res; 2014; 16(5):460. PubMed ID: 25606588
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral heterogeneity and subclonal diversification of early breast cancer.
Yates LR
Breast; 2017 Aug; 34 Suppl 1():S36-S42. PubMed ID: 28666921
[TBL] [Abstract][Full Text] [Related]
40. Functional genomics for breast cancer drug target discovery.
Yoshimaru T; Nakamura Y; Katagiri T
J Hum Genet; 2021 Sep; 66(9):927-935. PubMed ID: 34285339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
